MA26681A1 - Composes pyrazine - Google Patents
Composes pyrazineInfo
- Publication number
- MA26681A1 MA26681A1 MA25746A MA25746A MA26681A1 MA 26681 A1 MA26681 A1 MA 26681A1 MA 25746 A MA25746 A MA 25746A MA 25746 A MA25746 A MA 25746A MA 26681 A1 MA26681 A1 MA 26681A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazine compounds
- pyrazine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9818881.6A GB9818881D0 (en) | 1998-08-28 | 1998-08-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26681A1 true MA26681A1 (fr) | 2004-12-20 |
Family
ID=10838055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA25746A MA26681A1 (fr) | 1998-08-28 | 1999-08-27 | Composes pyrazine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6503909B1 (fr) |
| EP (1) | EP1107960A1 (fr) |
| JP (1) | JP2002523499A (fr) |
| KR (1) | KR20010079696A (fr) |
| CN (1) | CN1324349A (fr) |
| AU (1) | AU5624999A (fr) |
| BR (1) | BR9913183A (fr) |
| CA (1) | CA2341543A1 (fr) |
| CO (1) | CO5130006A1 (fr) |
| GB (1) | GB9818881D0 (fr) |
| MA (1) | MA26681A1 (fr) |
| PE (1) | PE20001022A1 (fr) |
| TR (1) | TR200100603T2 (fr) |
| TW (1) | TW429255B (fr) |
| WO (1) | WO2000012488A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1500653A1 (fr) * | 2000-02-16 | 2005-01-26 | Neurogen Corporation | Arylpyrazines substituées |
| CN1231473C (zh) | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| GB0010971D0 (en) * | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Process |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CA2484209C (fr) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Modulateurs de proteine kinase et procedes d'utilisation |
| EP1554258A1 (fr) | 2002-08-20 | 2005-07-20 | Neurogen Corporation | 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf |
| US7381409B2 (en) * | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
| EP1731609A4 (fr) * | 2004-03-30 | 2010-04-07 | Genomidea Inc | INHIBITEUR DE L'EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L'INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2460828A3 (fr) * | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Anticorps et diagnostic |
| WO2008061013A2 (fr) * | 2006-11-10 | 2008-05-22 | Amgen Inc. | Diagnostic et thérapie basés sur des anticorps |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| JP2011506483A (ja) * | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
| KR102918161B1 (ko) * | 2022-03-16 | 2026-01-28 | (주)아름테라퓨틱스 | 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도 |
| CN115611700B (zh) * | 2022-10-11 | 2024-06-14 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3575975A (en) * | 1968-07-25 | 1971-04-20 | Merck & Co Inc | Process for the preparation of 3-aminopyrazinoylureas |
| US3544568A (en) * | 1969-03-18 | 1970-12-01 | Merck & Co Inc | 3-amino-5,6-substituted pyrazinamides |
| US4402958A (en) | 1981-11-19 | 1983-09-06 | American Cyanamid Company | Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates |
| MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
-
1998
- 1998-08-28 GB GBGB9818881.6A patent/GB9818881D0/en not_active Ceased
-
1999
- 1999-08-26 WO PCT/EP1999/006248 patent/WO2000012488A1/fr not_active Ceased
- 1999-08-26 US US09/762,295 patent/US6503909B1/en not_active Expired - Fee Related
- 1999-08-26 CN CN99812550A patent/CN1324349A/zh active Pending
- 1999-08-26 EP EP99942919A patent/EP1107960A1/fr not_active Withdrawn
- 1999-08-26 BR BR9913183-8A patent/BR9913183A/pt not_active Application Discontinuation
- 1999-08-26 KR KR1020017002509A patent/KR20010079696A/ko not_active Withdrawn
- 1999-08-26 TR TR2001/00603T patent/TR200100603T2/xx unknown
- 1999-08-26 CA CA002341543A patent/CA2341543A1/fr not_active Abandoned
- 1999-08-26 PE PE1999000868A patent/PE20001022A1/es not_active Application Discontinuation
- 1999-08-26 JP JP2000567518A patent/JP2002523499A/ja active Pending
- 1999-08-26 AU AU56249/99A patent/AU5624999A/en not_active Abandoned
- 1999-08-27 TW TW088114723A patent/TW429255B/zh not_active IP Right Cessation
- 1999-08-27 MA MA25746A patent/MA26681A1/fr unknown
- 1999-08-27 CO CO99054338A patent/CO5130006A1/es unknown
-
2002
- 2002-08-12 US US10/216,399 patent/US20030022904A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1324349A (zh) | 2001-11-28 |
| TW429255B (en) | 2001-04-11 |
| US6503909B1 (en) | 2003-01-07 |
| US20030022904A1 (en) | 2003-01-30 |
| WO2000012488A1 (fr) | 2000-03-09 |
| BR9913183A (pt) | 2001-05-15 |
| CO5130006A1 (es) | 2002-02-27 |
| CA2341543A1 (fr) | 2000-03-09 |
| TR200100603T2 (tr) | 2001-07-23 |
| KR20010079696A (ko) | 2001-08-22 |
| PE20001022A1 (es) | 2000-10-16 |
| JP2002523499A (ja) | 2002-07-30 |
| AU5624999A (en) | 2000-03-21 |
| EP1107960A1 (fr) | 2001-06-20 |
| GB9818881D0 (en) | 1998-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69818643T2 (de) | Pyrazin-Verbindungen | |
| FR09C0030I2 (fr) | Composes thrombopoietiques | |
| ATE229954T1 (de) | Betacarbolinverbindungen | |
| ID28266A (id) | Senyawa-senyawa amidin | |
| DE69835302D1 (de) | Tintenbehälternachfüllsystem | |
| NO20011745L (no) | Forbindelser | |
| EP1076337A4 (fr) | Enregistreur-lecteur | |
| ID23761A (id) | Trisiklik tersubstitusi | |
| ID27004A (id) | Senyawa-senyawa kalsilitik | |
| EP1087957A4 (fr) | Composes auto-inducteurs | |
| ID23219A (id) | Trisiklik tersubstitusi | |
| NO20006662L (no) | Fluorfenylresin-forbindelser | |
| MA26587A1 (fr) | Composes de triazine | |
| FI980735A0 (fi) | Foerfarande foer hantering av foerdroejning | |
| DE69913027D1 (de) | Verdampfer | |
| DE69938388D1 (de) | Empfänger | |
| DE59911610D1 (de) | Substituierte benzoylcyclohexandione | |
| EP1105133A4 (fr) | Composes tricycliques | |
| ATE303996T1 (de) | Substituierte acylaminophenyl-uracile | |
| DE59912188D1 (de) | Substituierte phenyluracile | |
| NO980270L (no) | Trekkanordning | |
| ATA32198A (de) | Beschlag | |
| DE69838138D1 (de) | Empfänger | |
| FR2782553B1 (fr) | Evaporateur | |
| DE59911430D1 (de) | Zungenverbindung |